CF PharmTech, Inc. (H-share) disclosed a Next Day Return confirming the on-market repurchase of 18,500 ordinary shares on 24 April 2026. The buyback was executed at prices ranging from HK$20.54 to HK$20.84 per share, representing an average cost of roughly HK$20.66 and a total outlay of HK$0.38 million.

Following the transaction, the company’s issued share capital (excluding treasury shares) fell from 301.61 million to 301.59 million shares, a marginal reduction of 0.0061%. Treasury stock rose to 631,500 shares, while the total issued shares remained unchanged at 302.22 million.

The repurchase forms part of the mandate approved on 16 December 2025, which authorises CF PharmTech to buy back up to 30.22 million shares. Cumulative purchases under this mandate now stand at 631,500 shares, equivalent to 0.209% of the issued share count on the mandate date. Under Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 24 May 2026.